OS Therapies Announces Positive Phase 2b Data for OST-HER2 in Osteosarcoma

OS Therapies announced positive one-year event-free survival (EFS), overall survival, and safety data from its Phase 2b trial of OST-HER2 in patients ...
Home/KnloSights/Clinical Trial Updates/OS Therapies Announces Positive Phase 2b Data for OST-HER2 in Osteosarcoma